CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

Thomas P Miller, StephenE Jones

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.

Original languageEnglish (US)
Pages (from-to)358-360
Number of pages3
JournalThe Lancet
Volume313
Issue number8112
DOIs
StatePublished - Feb 17 1979

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Non-Hodgkin's Lymphoma
Doxorubicin
Disease-Free Survival
Radiotherapy
Clinical Trials
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA. / Miller, Thomas P; Jones, StephenE.

In: The Lancet, Vol. 313, No. 8112, 17.02.1979, p. 358-360.

Research output: Contribution to journalArticle

Miller, Thomas P ; Jones, StephenE. / CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA. In: The Lancet. 1979 ; Vol. 313, No. 8112. pp. 358-360.
@article{cfdd95c2dbdf4aedb9a852fcffe2fdd8,
title = "CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA",
abstract = "22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95{\%}) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.",
author = "Miller, {Thomas P} and StephenE Jones",
year = "1979",
month = "2",
day = "17",
doi = "10.1016/S0140-6736(79)92894-0",
language = "English (US)",
volume = "313",
pages = "358--360",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8112",

}

TY - JOUR

T1 - CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

AU - Miller, Thomas P

AU - Jones, StephenE

PY - 1979/2/17

Y1 - 1979/2/17

N2 - 22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.

AB - 22 patients with localised (stage I or II) diffuse lymphoma were treated with chemotherapy at the time of diagnosis. 14 patients received chemotherapy as the only treatment, and 8 received chemotherapy plus local irradiation. Doxorubicin-containing drug regimens were used in 20 patients. All 22 patients achieved a complete remission and remain alive with a median survival from the time of diagnosis of 27+ months. 21 patients (95%) have remained continuously free of disease with a median disease-free survival from the completion of chemotherapy of 23+ months. These findings provide a strong rationale for further clinical trials of chemotherapy alone or chemotherapy followed by regional radiotherapy for localised stages of diffuse lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0018744047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018744047&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(79)92894-0

DO - 10.1016/S0140-6736(79)92894-0

M3 - Article

C2 - 85006

AN - SCOPUS:0018744047

VL - 313

SP - 358

EP - 360

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8112

ER -